共 50 条
- [1] Preclinical development of the CDK4 selective inhibitor PF-07220060: Increased CDK4 versus CDK6 inhibition leads to improved anti-tumor efficacy at therapeutic concentrationsCANCER RESEARCH, 2024, 84 (06)Anders, LarsPascual, BernadetteBoras, BrittonCianfrogna, JulieGarza, ScottLi, NaYuan, Jing TangMoen, MarkHuser, NanniGallego, GaryJalaie, MehranNinkovic, SachaCho-Schultz, SujinShen, HongKath, JohnDress, KlausDiehl, WadeNair, SajivJones, RhysLafontaine, JenniferMurtaza, AnwarSacaan, AidaChintharlapalli, SudhakarVanArsdale, Todd
- [2] Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+HER2-breast cancerANNALS OF ONCOLOGY, 2024, 35 : S365 - S365Anders, L.Van Arsdale, T.Chintharlapalli, S.Boras, B.Cianfrogna, J.Huser, N.Pascual, B.Shen, C.Qiu, M.Sacaan, A.Jones, R.
- [3] Structure-based design of potent CDK4 selective inhibitor.ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U24 - U24Honma, THayashi, KKawanishi, NYoshizumi, THashimoto, NSugimoto, TNakamura, KTakaki, TMachida, TFukasawa, KHirai, HIwama, TIkeura, CIkuta, MKamata, KSuzuki-Takahashi, IHayama, T
- [4] Characterization of a novel potent and selective CDK4/6 inhibitor and a resistance mechanismCANCER RESEARCH, 2012, 72Dai, KangLi, CongLiang, LingmingRong, MingingOrf, JessicaKeegan, KathyLi, ZhihongFu, JiashengMa, JiCarlson, TimMcGee, LarryMedina, JulioKamb, AlexanderWickramasinghe, Dineli
- [5] International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER22 advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitorJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Giordano, AntonioIgnatiadis, MichailBarrios, Carlos H., Sr.Bidard, Francois ClementXu, BingheVana, Alicia M.Gong, JasonHolynskyj, AriadnaGopalakrishna, PrashanthRugo, Hope S.
- [6] Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced MyelosuppressionJOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 1446 - 1472Shi, WeiWang, RongQian, JianqiangWang, LuLi, YouMi, YahuiJia, ZhaotongPan, MingshiZhang, XiaoqiYe, WencaiXiong, FeiHu, XiaolongWang, Hao
- [7] Preclinical development of a highly potent and selective dual inhibitor of CDK4/6 for the treatment of cancerCANCER RESEARCH, 2018, 78 (13)Bantie, LaychiluhTadesse, SolomonLikisa, JimmaYu, MingfengNoll, BenjaminAlbrecht, HugoMilne, RobertWang, Shudong
- [8] Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2L metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitorsANNALS OF ONCOLOGY, 2024, 35 : S392 - S393Yap, T. A.Liu, F.Zhang, H.Roh, W.Giordano, A.Hamilton, E. P.Delioukina, M. L.Lira, M.Park, J.Basu, C.Sharma, M. R.
- [9] First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+HER2-mBC who progressed on prior CDK4/6 inhibitors and endocrine therapyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Yap, Timothy A.Giordano, AntonioHamilton, Erika P.LoRusso, PatriciaBowers, MichelleBasu, CynthiaBillotte, StephaneDelioukina, MariaLiu, FengYang, JingSharma, Manish